Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2024 U.S. Biopharma Recap

The biopharma sector got a much-needed shot in the arm with the Federal Reserve’s highly anticipated rate cut in September, the first since March 2020. Major indices recovered from broader volatility experienced this summer and ended the quarter near multi-year highs. Despite the traditional summer slowdown, the IPO window reopened after Labor Day with four pricings and two additional IPOs expected to price in early October. Overall secondary activity has already surpassed 2023 totals and the private financing market is on track to exceed last year.

Meanwhile, overall dealmaking was anemic during the quarter, with only one public M&A transaction announced valued at over $1 billion (Lilly/Morphic) and 10 partnering deals announced with more than $50 million in upfront proceeds. All eyes now shift towards November’s U.S. presidential election and the Federal Reserve’s ongoing easing cycle as the biopharma sector sets itself up for a broader recovery in 2025.

William Blair's biopharma team shares additional perspectives on the biopharma environment and what to expect heading into 2025.

Complete the form below to download a copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Navigating a Dynamic Lending Market With an Outside Debt Advisor

    Traversing the vast and ever-changing lending market is no easy task—especially given how much lenders vary when it comes to appetites and terms.

    Read more
  • FMX Has Received a Strategic Growth Investment from Luminate Capital Partners

    William Blair acted as exclusive financial advisor to FMX in connection with its strategic growth investment from Luminate Capital Partners.

    Read more
  • Ortholite Has Agreed to be Acquired by Coats Group plc

    William Blair acted as the lead financial advisor to Ortholite, a portfolio company of Trilantic Capital Partners, in connection with its pending sale to Coats Group plc (LSE: COA) for an enterprise value of $770 million excluding value ascribed to tax attributes and a royalty agreement for recently introduced intellectual property that was yet to be commercialized in the market.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures